Inflammatory Bowel Disease Perspective

 
 
  • GLP-1 RAs: When Not to Prescribe   Dr Tamaan K. Osbourne-Roberts reviews the list of patients who probably should not be taking GLP-1 receptor agonists.
  • The Year in Gastroenterology: 10 Must-Read Studies In a year of pivotal gastroenterology research, these 10 articles were in a class of their own, according to Dr David Johnson.
  • New Directions in Anemia and Related Disorders From ASH 2024   Strategies to reduce disease burden in alpha- or beta-thalassemia, sickle cell disease, and polycythemia vera, and insights into anemia in IBD, are among anemia highlights from ASH 2024.
  • Exocrine Pancreatic Insufficiency (EPI): 5 Things to Know From nutritional deficiencies to irksome GI manifestations, EPI can cause a wide range of complications. Here are five things to know about this often underrecognized condition.
  • Health Maintenance in Ulcerative Colitis: 5 Things to Know Drs Sandra Naffouj and Emanuelle Bellaguarda outline key tips for maintaining health in patients with ulcerative colitis.
  • Diagnosis & Management of Exocrine Pancreatic Insufficiency   Diagnosing exocrine pancreatic insufficiency can be vexing to clinicians, but missing it may deprive patients of access to effective, lifesaving therapies, according to Dr David Whitcomb.
  • ACG 2024 8 New GI Studies With Practice-Shifting Implications   Dr David Johnson highlights studies on increasing disease rates, the surprising effects of palliative care consultations, and drugs on the verge of approval.
  • The Role of Therapeutic Diets in Crohn’s Disease Management Several studies suggest that diet plays a vital role in the etiopathogenesis of Crohn’s disease. Experts share their insights on the optimal use of diet in helping patients manage symptoms.
  • ACG 2024 Promising New Drug Data for Several Common GI Conditions   This year’s American College of Gastroenterology meeting featured encouraging findings for apraglutide, vonoprazan, rifaximin, and biologics in conditions ranging from heartburn to colitis.
  • ACG 2024 Read clinically focused news coverage of key developments from ACG 2024
  • Understanding the Triggers Behind IBD and IBS   Microbial imbalance can lead to IBD and IBS. Researchers are using sophisticated analysis and exploring microbiome replacement therapies to improve outcomes for these gut-related conditions.
  • Managing Acute Severe UC: Emerging Strategies   Dr Edward Barnes discusses new approaches for improving patient outcomes in acute severe ulcerative colitis.
  • UEG 2024 Read clinically focused news coverage of key developments from UEG 2024
  • A Patient-Centered Focus in Crohn's Disease Management Although several treatment options exist in the management of Crohn's disease, a patient-centered approach is integral amid the challenges of addressing symptoms and optimizing patient care.
  • Comorbidities Associated With Psoriasis: 5 Things to Know Psoriasis-associated comorbidities can have a significant impact on a patient's quality of life. Clinicians should be aware of these co-existing conditions for screening and appropriate co-management.
  • Key Tips for Integrating New Ulcerative Colitis Therapies   Dr Jordan Axelrad discusses practical considerations for adding novel, targeted therapies in ulcerative colitis management.
  • In Colonoscopy, Quality Indicators Aren't Optional   Dr David Johnson explains why the ACG/ASGE's recommendations on achieving quality colonoscopy are far from mere suggestions.
  • Optimal Management of Perianal Disease in Crohn's Disease Although treatment and management of perianal disease in Crohn's disease can be challenging, a multidisciplinary approach is integral to optimizing patient care.
  • The Oral Microbiome's Role in Promoting GI Disease   Dr David Johnson explores the latest data linking oral health to diseases such as colorectal cancer, cirrhosis, and inflammatory bowel disease.
  • Vitamin D: Who Benefits From Supplements Now?   Dr JoAnn Manson highlights the subgroups of the population that may still need a vitamin D supplement, even if screening isn't recommended.